Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis

• Status: Completed
• Trial end date: 1997-12-01
• Target enrollment: 0
• Participant gender: All

Summary

OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma).

II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Stanford University
• Treatments: Methocarbamol

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• Progressive systemic sclerosis (scleroderma)

• No pregnant or nursing women